PIPE-791 is under clinical development by Contineum Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PIPE-791’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PIPE-791 overview
PIPE-791 is under development for the treatment of primary progressive multiple sclerosis, secondary progressive multiple sclerosis, progressive relapsing multiple sclerosis, idiopathic pulmonary fibrosis, chronic pain associated with osteoarthritis (OA) and low back pain (LBP) and neuroinflammation. It acts by targeting lysophosphatidic acid receptor 1 (LPA1R) and is administered through oral route in the form of tablets.
Contineum Therapeutics overview
Contineum Therapeutics is a clinical stage biopharmaceutical company that focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I). Its pipeline products include PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective inhibitor of the M1 receptor for relapse remitting multiple sclerosis (RRMS) and depression; and LPA1 receptor antagonist. Contineum Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of PIPE-791’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
